Alemtuzumab + Rabbit Anti-Human Thymocyte Globulin
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreas-Kidney Transplantation
Conditions
Pancreas-Kidney Transplantation
Trial Timeline
Apr 1, 2006 → Jun 1, 2011
NCT ID
NCT00316810About Alemtuzumab + Rabbit Anti-Human Thymocyte Globulin
Alemtuzumab + Rabbit Anti-Human Thymocyte Globulin is a phase 3 stage product being developed by Astellas Pharma for Pancreas-Kidney Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00316810. Target conditions include Pancreas-Kidney Transplantation.
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00316810 | Phase 3 | Completed |